This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.03% per year. These returns cover a period from January 1, 1988 through July 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Staar Surgical (STAA) Beats Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Staar Surgical (STAA) delivered earnings and revenue surprises of 33.33% and 4.15%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Staar Surgical (STAA) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Staar Surgical (STAA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Staar Surgical (STAA) Beats Q2 Earnings Estimates
by Zacks Equity Research
Staar Surgical (STAA) delivered earnings and revenue surprises of 40.00% and -1.09%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Staar Surgical (STAA) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Staar Surgical (STAA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
The Zacks Analyst Blog Highlights: Herman Miller, Clean Harbors, Great Lakes Dredge & Dock and STAAR Surgical
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Herman Miller, Clean Harbors, Great Lakes Dredge & Dock and STAAR Surgical
4 Stocks to Buy From Sectors With Top Job Gains
by Zacks Equity Research
New job additions across business services, construction and healthcare were prominent in April.
Zacks.com featured highlights include: Ralph Lauren, Nu Skin, Tilly's, Centene and STAAR
by Zacks Equity Research
Zacks.com featured highlights include: Ralph Lauren, Nu Skin, Tilly's, Centene and STAAR
Ride on Rising P/E Investing With These 5 Top-Ranked Stocks
by Sanghamitra Saha
Want to try an out-of-the-box approach? Tap five stocks with increasing P/E ratios.
Analysts Estimate Staar Surgical (STAA) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Staar Surgical (STAA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Has STAAR Surgical (STAA) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Is (STAA) Outperforming Other Medical Stocks This Year?
4 Healthcare Stocks That Popped More Than 100% in 2018
by Sapna Bagaria
Players in the Healthcare sector gained from aging population, expanding government business, technological investment, strong demand for its product and services and industry consolidation.
Here's Why You Should Buy Express Scripts (ESRX) Stock Now
by Zacks Equity Research
Strong demand for Express Scripts' (ESRX) solutions like SafeGuardRx, 90-day supply for chronic medications, exclusive Accredo Specialty Pharmacy and advanced opioid solutions buoy optimism.
4 Medical Device Stocks That More Than Doubled in 2018
by Sweta Jaiswal
Here are four medical device stocks which have performed really well in 2018 and should be on investors' radar next year as well.
Here's Why You Should Hold Allscripts Stock in Your Portfolio
by Zacks Equity Research
Allscripts (MDRX) has been winning contracts in the Sunrise EHR platform; competition stiff.
Express Scripts Announces 3-Year Agreement With Walmart
by Zacks Equity Research
Express Scripts (ESRX) and Walmart (WMT) collaborate to increase affordable access of the expensive prescription drugs for insured and uninsured patients.
BD Gets Enterprise Level Cybersecurity Assessment From UL
by Zacks Equity Research
BD (BDX) receives UL CAP for BD FACSLyric flow cytometer with BD FACSuite Clinical software.
Here's Why Investors Should Hold Masimo (MASI) Stock Now
by Zacks Equity Research
Masimo (MASI) gains from solid prospects in the SET Pulse Oximeter platform. However, cutthroat competition in the MedTech space is likely to hurt the stock.
Ecolab to Boost Food Safety Standards With Holchem Buyout
by Zacks Equity Research
Ecolab (ECL) to benefit from Holchem Group's unique offerings for the food and beverage, foodservice and hospitality industries.
Here's Why Investors Should Hold AngioDynamics Stock Now
by Zacks Equity Research
AngioDynamics' (ANGO) gains from solid prospects in the NanoKnife platform. However, sluggishness in the Venous Insufficiency business is a headwind.
Veeva Systems Announces New DAM Solution for Life Sciences
by Zacks Equity Research
Veeva Vault Digital Publishing uses Veeva Systems' (VEEV) flagship Vault PromoMats or Vault MedComms platforms for updating digital content. The platform leverages on Amazon CloudFront.
Here's Why You Should Hold Pacific Biosciences (PACB) Now
by Zacks Equity Research
Pacific Biosciences (PACB) is likely to gain from strong prospects in the Sequel System platform. However, the company faces cutthroat competition in the DNA sequencing market.
Here's Why You Should Invest in Accuray (ARAY) Stock Now
by Zacks Equity Research
Accuray's (ARAY) benefits from growing adoption of non-surgical treatment options among cancer patients and increasing demand for its latest offerings.
Ecolab to Buy Bioquell for Healthcare & Life Sciences' Growth
by Zacks Equity Research
Ecolab (ECL) to leverage on Bioquell's innovative bio-decontamination and isolator platforms for residue-free surface decontamination.
Cardinal Health to Highlight Cost-Control Approach in ASHP
by Zacks Equity Research
Cardinal Health (CAH) helps hospitals identify hidden savings, improve patient outcomes and drive supply chain efficiencies.
Here's Why Investors Should Hold Medidata (MDSO) Stock Now
by Zacks Equity Research
Solid prospects in the Rave Genomics platform are likely to provide Medidata (MDSO) a competitive edge in the MedTech space.